Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SB-747651A is an inhibitor of p90 ribosomal S6 kinase 1 (MSK1; IC50 = 0.5 nM).1 It is selective for MSK1 over Rho-associated kinase 1 (ROCK1), p70 ribosomal S6 kinase (p70S6K), dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), and cyclin-dependent kinase 2 (Cdk2; IC50s = 100, 270, 4,900, and >10,000 nM, respectively) and is greater than 300-fold selective over glycogen synthase kinase 3 (GSK3) and p90 ribosomal S6 kinase 1 (RSK1). SB-747651A (2 mg/kg, i.p.) reduces tumor volume and metastasis in a PANC-1 pancreatic cancer mouse xenograft model and reduces tumor volume in a patient-derived xenograft (PDX) mouse model of pancreatic cancer.2
WARNING This product is not for human or veterinary use.
1. (1H-
2. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Rep. Med. 4(11), 101285 (2023).